The Treatment Effect of Endoscopic Evacuation Versus Suboccipital Craniotomy for Spontaneous Intracerebellar Hemorrhage.

Inclusion Criteria: 1. Aged 18-80 years old; 2. Cerebellar hemorrhage was confirmed by computed tomography (CT) scans; 3. The hematoma was \> 3 cm in diameter or the hematoma volume was \> 10ml or the hemorrhage is associated with brainstem compression or hydrocephalus; 4. The randomization can be conducted within 24 hours; 5. GCS score at randomization was 5-14; 6. mRS was 0-1 before onset; 7. The systolic pressure was controlled below 180 mmHg before randomization; 8. Informed consent was obtained from the patient and his legal representative. Exclusion Criteria: 1. Coexistent intracranial bleeding from other sites; 2. Brain herniation before randomization; 3. Bleeding caused by other reasons such as aneurysm, arteriovenous malformation, trauma, and tumor; hemorrhage secondary to large cerebral infarction, beta-amyloid degeneration disease, or coagulation dysfunction; coexistent aneurysm, arteriovenous malformation, brain trauma, brain tumors, large area cerebral infarction, beta-amyloid degeneration disease, or serious blood coagulation disorders; 4. A history of cerebral hemorrhage within 1 year; 5. A history of intracranial surgery or hemorrhagic disease (intracerebral hemorrhage, subarachnoid hemorrhage, subdural or epidural hemorrhage) within the last 30 days; 6. Hemoglobin \< 100g/L, hematocrit \< 25%, platelet count \<100\*10\^9/L; 7. Warfarin, dabigatran, rivaroxaban, and other anticoagulant drugs were given within one week before enrollment, and the INR was \> 1.4; 8. Aspirin, clopidogrel, ticagrelor, and other antiplatelet drugs were given within one week before enrollment, and the inhibition rate of AA-dependent pathway \> 50%，inhibition rate of ADP-dependent pathway \> 30%; 9. Long-term anticoagulation and antiplatelet therapy is needed; 10. A history of internal bleeding that is not completely controlled, such as gastrointestinal bleeding, genitourinary bleeding, respiratory bleeding; 11. Myocardial infarction within 30 days; 12. Patients with high risks of embolization (a history of mechanical heart valve implantation, left ventricular thrombosis, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis); atrial fibrillation without mitral stenosis is acceptable; 13. Severely impaired liver function (ALT \> 3 times the normal upper limit, or AST \> 3 times the normal upper limit); severely impaired renal function (glomerular filtration rate \< 30ml/min/1.73m2); 14. Hypertension could not be effectively controlled before randomization (systolic blood pressure ≥ 180 mmHg); 15. Patients cannot complete the follow-up due to Alzheimer's disease or mental illness; 16. Coexistent serious diseases of the respiratory, circulatory, digestive, urogenital, endocrine, immune, and blood systems that are likely to interfere with the results; 17. Patients with current drug/alcohol abuse or dependence, or expected to have poor compliance and difficult to complete the follow-up; 18. Allergic to the drugs or instruments used in surgery; 19. Patients with surgery contraindications, or the other factors that may preclude implementation of the study protocol; 20. Pregnant or lactating women; 21. Life expectancy \< 12 months due to any advanced stage of disease; 22. Patient is participating in other clinical trials; 23. The legal guardian of the patient is unwilling to sign the written informed consent; 24. Assessed unsuitable for inclusion by investigators.